skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8127

Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma

Review

(1562) Views  (555) Full article downloads

Authors: Nousheen Samad, Anas Younes

Published Date September 2010 Volume 2010:3 Pages 167 - 178
DOI: http://dx.doi.org/10.2147/OTT.S8147

Nousheen Samad1, Anas Younes2

1Division of Pharmacy, Pharmacy Clinical Programs, 2Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Abstract: Mantle cell lymphoma (MCL) is a rare and aggressive subtype of lymphoma associated with a poor prognosis. Chemotherapy is the mainstay of frontline treatment for patients with this disease. Despite high response rates to combination chemotherapy regimens, the majority of patients relapse within a few years of treatment. Therefore, finding efficacious treatments for relapsed or refractory disease has become a growing area of clinical research. The mammalian target of rapamycin (mTOR) is responsible for integrating cell signals from growth factors, hormones, and nutrients and communicating energy status. Scientific research on aberrant molecular pathways in cancer has revealed that several proteins along the mTOR pathway may be upregulated in this and other types of lymphoma. Temsirolimus is the first mTOR inhibitor that has shown clinical efficacy in treating MCL that has relapsed after frontline treatments.

Keywords: rapamycin, CCI-779, MCL, mTOR, PI3K, Akt